Elizabeth A Reap

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10420776/publications.pdf

Version: 2024-02-01

20 papers 3,629 citations

471061 17 h-index 19 g-index

20 all docs

20 docs citations

times ranked

20

4892 citing authors

#	Article	IF	CITATIONS
1	Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature, 2001, 411, 207-211.	13.7	1,060
2	Delayed Apoptotic Cell Clearance and Lupus-like Autoimmunity in Mice Lacking the c-mer Membrane Tyrosine Kinase. Journal of Experimental Medicine, 2002, 196, 135-140.	4.2	565
3	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature, 2015, 519, 366-369.	13.7	429
4	Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma. Human Gene Therapy, 2012, 23, 1043-1053.	1.4	266
5	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clinical Cancer Research, 2014, 20, 972-984.	3.2	254
6	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research, 2017, 23, 1898-1909.	3.2	215
7	Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine, 2009, 28, 484-493.	1.7	189
8	A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. PLoS ONE, 2012, 7, e31046.	1.1	98
9	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.4	82
10	A Supramolecular Vaccine Platform Based on \hat{l}_{\pm} -Helical Peptide Nanofibers. ACS Biomaterials Science and Engineering, 2017, 3, 3128-3132.	2.6	74
11	Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine, 2007, 25, 8180-8189.	1.7	62
12	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. Cancer Immunology Research, 2013, 1, 163-167.	1.6	61
13	Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine, 2007, 25, 7441-7449.	1.7	56
14	Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts. Clinical Cancer Research, 2019, 25, 358-368.	3.2	51
15	Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins. Vaccine Journal, 2007, 14, 748-755.	3.2	44
16	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Clinical Cancer Research, 2018, 24, 3611-3631.	3. 2	39
17	Immunotherapy for malignant glioma. , 2015, 6, 68.		36
18	The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice. Seminars in Immunology, 1994, 6, 49-54.	2.7	23

#	Article	IF	CITATIONS
19	Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncolmmunology, 2014, 3, e944054.	2.1	19
20	Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 205-211.	2.0	6